Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: BIO BRKR TWST GKOS A MTD WAT RMD DHR TMO

| Held by: VTI VXF IBB SCHA VHT ITOT GNOM SCHB MSSM PRFZ

Index	-
Market Cap	279.67M
Enterprise Value	-168.96M
Income	-87.38M
Sales	84.60M
Book/sh	1.38
Cash/sh	1.21
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	389
IPO	Feb 10, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	3.31
P/B	0.52
P/C	0.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.00
Quick Ratio	8.80
Current Ratio	9.10
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-0.23
EPS next Y	-0.16
EPS next Q	-0.02
EPS this Y	33.33%
EPS next Y	-60.00%
EPS next 5Y	-
EPS past 3/5Y	56.76% 23.22%
Sales past 3/5Y	-4.49% -9.19%
EPS Y/Y TTM	29.58%
Sales Y/Y TTM	-45.15%
EPS Q/Q	22.07%
Sales Q/Q	-7.62%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-446.88% -3.37%

Insider Own	4.14%
Insider Trans	0.00%
Inst Own	75.40%
Inst Trans	-8.32%
ROA	-9.11%
ROE	-11.18%
ROIC	-15.54%
Gross Margin	49.14%
Oper. Margin	-74.04%
Profit Margin	-103.29%
SMA20	-12.24%
SMA50	-14.92%
SMA200	-35.15%
Trades

Shs Outstand	392.12M
Shs Float	376.32M
Short Float	0.72%
Short Ratio	0.80
Short Interest	2.69M
52W High	1.72 -58.58%
52W Low	0.70 1.35%
Volatility	5.58% 7.49%
ATR (14)	0.05
RSI (14)	35.74
Beta	1.35
Rel Volume	0.04
Avg Volume	3.39M
Volume	7,008

Perf Week	-9.69%
Perf Month	-20.39%
Perf Quarter	-27.66%
Perf Half Y	-36.39%
Perf YTD	-44.34%
Perf Year	-42.08%
Perf 3Y	-73.81%
Perf 5Y	-89.43%
Perf 10Y	-92.26%
Recom	3.00
Target Price	1.35
Prev Close	0.71
Price	0.71
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	TD Cowen	Buy → Hold	$1.55
Feb-27-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Aug-05-26 04:25PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press)
04:05PM	Standard BioTools Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 08:00AM	Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences (GlobeNewswire)
Jul-22-26 07:00AM	Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire) -7.43%
Jul-21-26 02:53PM	Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire)
07:30AM	Loading…
Jul-20-26 07:30AM	Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction (GlobeNewswire) -5.02%
Jun-15-26 01:29PM	Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-09-26 07:50AM	Stealthy startup Treeline plans a reverse merger (BioPharma Dive) +10.33%
Jun-08-26 07:30AM	Standard BioTools and Treeline Biosciences Announce Merger Agreement (GlobeNewswire) -30.16%
May-05-26 05:38PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press)
04:05PM	Standard BioTools Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-21-26 07:00AM	Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Feb-24-26 04:34PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 07:00AM	Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
09:09AM	Loading…
Jan-30-26 09:09AM	Standard BioTools Completes Sale of SomaLogic to Illumina (GlobeNewswire)
Jan-08-26 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue (GlobeNewswire) +20.31%
Nov-19-25 11:30AM	Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry (Business Wire)
Nov-10-25 12:15PM	Illumina Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
Nov-04-25 05:31PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 08:01AM	Earnings To Watch: Standard BioTools Inc (LAB) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 07:00AM	Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 (GlobeNewswire)
Sep-03-25 09:15AM	Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development (PR Newswire)
Aug-11-25 07:00PM	Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:25AM	What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 05:30PM	Doximity (DOCS) Q1 Earnings and Revenues Top Estimates (Zacks)
Aug-06-25 07:00AM	Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study (GlobeNewswire)
07:00AM	Loading…
Jul-21-25 07:00AM	Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 (GlobeNewswire)
Jun-26-25 08:07AM	Illumina Stock May Benefit From New Agreement to Acquire SomaLogic (Zacks)
Jun-25-25 12:16AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire)
Jun-23-25 07:13AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire) +17.14%
07:05AM	Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina (GlobeNewswire)
06:58AM	Illumina to buy SomaLogic for up to $425M (MedTech Dive)
May-30-25 07:00AM	Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series (GlobeNewswire)
May-09-25 05:00PM	Labrador Gold Announces Resignation of Director Kai Hoffmann (GlobeNewswire) +8.41%
May-07-25 08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.83%
04:01PM	Standard BioTools Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 10:10AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 07:00AM	Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 (GlobeNewswire)
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +6.72%
07:00AM	Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 (GlobeNewswire)
Feb-27-25 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.68%
07:09AM	Q4 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
02:22AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Feb-26-25 06:52PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance) -7.14%
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 10:54AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.26%
Feb-12-25 07:00AM	Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 (GlobeNewswire)
Jan-13-25 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue (GlobeNewswire) +26.38%
Jan-08-25 07:00AM	Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine (GlobeNewswire)
Dec-19-24 08:00AM	Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 08:00AM	Standard BioTools Appoints Alex Kim as Chief Financial Officer (GlobeNewswire)
Oct-31-24 11:00AM	Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
08:01AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 05:20PM	Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.43%
04:15PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-21-24 09:03PM	Millennium Management LLC Acquires Shares in Standard BioTools Inc (GuruFocus.com)
Oct-16-24 08:00AM	Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire)
Oct-03-24 04:56AM	Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-24-24 08:00AM	Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform (GlobeNewswire) +5.35%
Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

PresidentDr. Michael Egholm Ph.D.

Chief Financial OfficerMr. Hanjoon Kim

Senior VP & Chief Business OfficerMr. Sean Mackay

VP & Chief Accounting OfficerMr. Jonathan Mickelsen

Vice President of Investor RelationsJohn Graziano

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Egholm Michael	President & CEO	Apr 06 '26	Option Exercise	0.00	196,513	0	6,790,596	Apr 08 09:55 PM
Kim Hanjoon Alex	Chief Financial Officer	Apr 06 '26	Option Exercise	0.00	70,183	0	2,800,702	Apr 08 09:55 PM
Casdin Partners Master Fund, L	Director	Dec 04 '25	Buy	1.45	150,000	217,020	72,100,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 02 '25	Buy	1.42	125,000	177,512	71,875,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 03 '25	Buy	1.44	75,000	108,037	71,950,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Nov 25 '25	Buy	1.30	7,550,000	9,838,405	71,750,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 24 '25	Buy	1.43	150,000	214,875	64,200,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 20 '25	Buy	1.30	450,000	586,260	64,050,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 19 '25	Buy	1.28	350,000	448,910	63,600,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 18 '25	Buy	1.23	275,000	339,405	63,250,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 13 '25	Buy	1.20	450,000	541,395	62,500,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 14 '25	Buy	1.24	250,000	309,800	62,750,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 17 '25	Buy	1.22	225,000	275,580	62,975,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 12 '25	Buy	1.19	375,000	445,838	62,050,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 11 '25	Buy	1.20	300,000	358,800	61,675,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 10 '25	Buy	1.17	275,000	321,915	61,375,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 07 '25	Buy	1.12	225,000	252,765	61,100,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Sep 09 '25	Buy	1.29	100,000	128,920	60,875,000	Sep 11 09:03 PM
Casdin Partners Master Fund, L	Director	Sep 04 '25	Buy	1.28	250,000	319,350	60,775,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Sep 03 '25	Buy	1.27	250,000	316,400	60,525,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Aug 22 '25	Buy	1.26	200,000	252,680	59,950,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 25 '25	Buy	1.24	200,000	248,180	60,150,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 26 '25	Buy	1.26	125,000	157,938	60,275,000	Aug 26 08:46 PM

BLFS Biolife Solutions Inc daily Stock Chart

Peers: RGEN TFX BAX TECH BDX RMD GKOS BSX EW MDT

| Held by: IJR VTI IWM SPSM VXF IWN VTWO SCHA IJT IJS

Index	RUT
Market Cap	1.66B
Enterprise Value	1.59B
Income	47.66M
Sales	102.82M
Book/sh	8.59
Cash/sh	1.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	155
IPO	Nov 22, 1989

P/E	35.06
Forward P/E	101.41
PEG	-
P/S	16.12
P/B	3.95
P/C	20.12
P/FCF	204.43
EV/EBITDA	248.25
EV/Sales	15.48
Quick Ratio	7.14
Current Ratio	9.69
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	0.97
EPS next Y	0.33
EPS next Q	0.05
EPS this Y	299.00%
EPS next Y	-32.81%
EPS next 5Y	-
EPS past 3/5Y	54.38% -55.02%
Sales past 3/5Y	-15.90% 14.88%
EPS Y/Y TTM	981.57%
Sales Y/Y TTM	0.17%
EPS Q/Q	376.10%
Sales Q/Q	11.98%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	2807.35% 2.41%

Insider Own	4.10%
Insider Trans	-39.37%
Inst Own	101.70%
Inst Trans	1.17%
ROA	12.09%
ROE	13.15%
ROIC	11.00%
Gross Margin	64.76%
Oper. Margin	2.90%
Profit Margin	46.35%
SMA20	3.83%
SMA50	14.87%
SMA200	37.06%
Trades

Shs Outstand	48.89M
Shs Float	46.90M
Short Float	9.69%
Short Ratio	4.06
Short Interest	4.54M
52W High	35.35 -4.10%
52W Low	17.86 89.81%
Volatility	2.50% 3.70%
ATR (14)	1.23
RSI (14)	63.05
Beta	1.91
Rel Volume	0.00
Avg Volume	1.12M
Volume	124

Perf Week	-2.14%
Perf Month	16.30%
Perf Quarter	63.29%
Perf Half Y	52.50%
Perf YTD	40.20%
Perf Year	39.28%
Perf 3Y	193.76%
Perf 5Y	-23.49%
Perf 10Y	1703.19%
Recom	2.78
Target Price	31.12
Prev Close	35.07
Price	33.90
Change %	-3.34%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-26	Downgrade	The Benchmark Company	Buy → Hold
Jul-22-25	Resumed	Stephens	Overweight	$30
Sep-30-24	Initiated	H.C. Wainwright	Buy	$29
Apr-04-24	Initiated	Jefferies	Buy	$22
Jul-11-23	Initiated	Craig Hallum	Buy	$29
Apr-25-22	Upgrade	Oppenheimer	Perform → Outperform	$28
Oct-19-21	Initiated	B. Riley Securities	Buy	$61
Oct-15-21	Resumed	Cowen	Outperform	$64
May-14-21	Downgrade	The Benchmark Company	Buy → Hold
Mar-23-21	Upgrade	The Benchmark Company	Hold → Buy	$54
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$40
Sep-22-20	Downgrade	Oppenheimer	Outperform → Perform
Sep-18-20	Initiated	Cowen	Outperform	$33
Aug-11-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-08-20	Reiterated	Maxim Group	Buy	$18 → $26
Feb-24-20	Initiated	Lake Street	Buy	$25
Feb-19-20	Initiated	The Benchmark Company	Buy	$24
Feb-06-20	Resumed	B. Riley FBR	Buy	$27
Jan-08-20	Initiated	Stephens	Overweight	$23
Nov-21-19	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

Aug-06-26 04:03PM	BioLife Solutions Reports Second Quarter 2026 Financial Results (PR Newswire)
Jul-28-26 10:44AM	Are NG, BLFS, NRIM Obtaining Fair Deals for their Shareholders? (PR Newswire) +7.35%
10:05AM	Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance (InvestorsHub)
Jul-23-26 12:10PM	Are UTZ, BLFS, FNWD Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-29-26 07:06PM	Orthofix Medical and 5 More Stocks See Action From Activist Investors (Barrons.com) +6.86%
08:30AM	Loading…
May-08-26 08:30AM	BioLife Solutions, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 04:03PM	BioLife Solutions Reports First Quarter 2026 Financial Results (PR Newswire) +6.30%
Apr-23-26 04:03PM	BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 (PR Newswire)
Apr-21-26 04:15PM	BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal CryoCase (PR Newswire)
Mar-02-26 09:55AM	Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade (Zacks) -6.94%
Feb-27-26 12:07AM	BioLife Solutions Inc (BLFS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +7.65%
Feb-26-26 08:03PM	BioLife Solutions, Inc. Q4 2025 Earnings Call Summary (Moby)
06:00PM	BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:48PM	BioLife Solutions Q4 Earnings Call Highlights (MarketBeat)
04:03PM	BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations (PR Newswire)
08:04AM	Loading…
Feb-17-26 08:04AM	BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026 (PR Newswire)
Feb-12-26 08:03AM	BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market (PR Newswire)
Feb-11-26 05:25PM	QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-03-26 12:02PM	Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions (Zacks)
05:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Revised) (Zacks)
Feb-02-26 09:08AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Jan-12-26 08:03AM	BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations (PR Newswire)
Nov-25-25 12:42PM	Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall (Zacks)
Nov-20-25 08:04AM	BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence (PR Newswire)
Nov-18-25 04:01AM	Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion (Zacks)
Nov-17-25 09:20AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
07:15AM	BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025 (PR Newswire)
Nov-10-25 06:15AM	New Strong Buy Stocks for November 10th (Zacks)
Nov-07-25 12:01AM	BioLife Solutions Inc (BLFS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 05:35PM	BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:03PM	Loading…
04:03PM	BioLife Solutions Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-05-25 08:00PM	Flora Growth Corp. (FLGC) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-23-25 04:03PM	BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025 (PR Newswire)
Oct-08-25 12:31PM	Peli BioThermal expands cold chain capabilities with EVO acquisition (FreightWaves)
Oct-07-25 08:04AM	BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary (PR Newswire)
Sep-09-25 09:40AM	Are Medical Stocks Lagging Bayer (BAYRY) This Year? (Zacks)
Aug-29-25 04:30PM	Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
09:55AM	Does BioLife Solutions (BLFS) Have the Potential to Rally 25.6% as Wall Street Analysts Expect? (Zacks)
Aug-15-25 11:12AM	Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed (Zacks)
Aug-14-25 08:33AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Aug-12-25 12:00PM	BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why (Zacks) +7.55%
09:55AM	Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions (BLFS): Here's What You Should Know (Zacks)
Aug-07-25 05:20PM	BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2 (Zacks) +9.88%
04:03PM	BioLife Solutions Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 07:05PM	MariMed Inc. (MRMD) Reports Break-Even Earnings for Q2 (Zacks)
Jul-28-25 09:07AM	Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations (Business Wire)
08:05AM	BioLife Solutions Makes Strategic Investment in Pluristyx (PR Newswire)
Jul-24-25 04:05PM	BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025 (PR Newswire)
Jul-03-25 01:51PM	Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts (Zacks)
Jun-20-25 06:48PM	E2open Parent, Mission Produce See Activist Action (Barrons.com)
Jun-19-25 01:03PM	Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas (Zacks)
Jun-05-25 09:55AM	How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72% (Zacks)
May-28-25 02:16PM	H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock (Insider Monkey)
May-21-25 01:22PM	EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint (Zacks)
05:26AM	Merit Medical acquires haemostatic device manufacturer Biolife for $120m (Medical Device Network)
May-14-25 08:03AM	BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025 (PR Newswire)
May-13-25 09:55AM	Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-09-25 03:38AM	BioLife Solutions Inc (BLFS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-08-25 05:25PM	BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	BioLife Solutions Updates Earnings Call Information (PR Newswire)
04:03PM	BioLife Solutions Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:45PM	Green Thumb Industries Inc. (GTBIF) Q1 Earnings and Revenues Miss Estimates (Zacks)
05:20PM	BioLife Solutions Q1 2025 Earnings Preview (Seeking Alpha)
10:23AM	What To Expect From BioLife Solutions Inc (BLFS) Q1 2025 Earnings (GuruFocus.com)
Apr-30-25 08:03AM	BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 (PR Newswire)
Apr-23-25 05:15PM	ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +11.24%
Apr-10-25 05:17AM	Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? (Zacks) -7.90%
Apr-07-25 08:03AM	BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company (PR Newswire) +5.08%
Apr-06-25 09:00AM	BioLife Solutions Stock: Back On Track, But Still Expensive (Seeking Alpha)
04:43AM	BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry (Seeking Alpha)
Mar-24-25 07:27AM	5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes (Zacks) +5.68%
Mar-18-25 08:30AM	BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair (PR Newswire)
Mar-04-25 02:00AM	BioLife Solutions Inc (BLFS) Q4 2024 Earnings Call Highlights: Strong Margin Growth and ... (GuruFocus.com)
Mar-03-25 11:43PM	Q4 2024 BioLife Solutions Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-28-25 07:10AM	What To Expect From BioLife Solutions Inc (BLFS) Q4 2024 Earnings (GuruFocus.com)
Feb-20-25 04:03PM	BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 (PR Newswire)
Jan-29-25 09:15AM	BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jan-24-25 09:40AM	Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-22-25 08:50AM	BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations (PR Newswire)
Dec-16-24 08:11AM	BioLife Solutions Appoints Tony J. Hunt to its Board of Directors (PR Newswire)
Nov-14-24 04:05PM	BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary (PR Newswire) -10.20%
Nov-13-24 02:16AM	BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ... (GuruFocus.com) -9.02%
Nov-12-24 05:45PM	BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioLife Solutions Reports Third Quarter 2024 Financial Results (PR Newswire)
08:05AM	BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary (PR Newswire)
Nov-11-24 07:11AM	What To Expect From BioLife Solutions Inc (BLFS) Q3 2024 Earnings (GuruFocus.com)
Oct-31-24 04:03PM	BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024 (PR Newswire)
Oct-21-24 09:40AM	Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? (Zacks)
Oct-09-24 05:55PM	BioLife Solutions Inc (BLFS) Q2 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -5.13%
Oct-07-24 08:50AM	Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going (Zacks)
Sep-30-24 09:41AM	Disney upgraded, JPMorgan downgraded: Wall Street's top analyst calls (The Fly)
Sep-17-24 09:40AM	Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? (Zacks) -7.89%
Aug-19-24 02:05AM	BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2 (Insider Monkey)
Aug-08-24 09:58PM	BLFS Stock Earnings: BioLife Solns Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +11.04%
05:45PM	BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:03PM	BioLife Solutions Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 03:56PM	Is BioLife Solutions, Inc. (BLFS) the Best Organ Transplant and Diagnosis Stock to Buy Now? (Insider Monkey)

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

CEO & ChairmanMr. Roderick de Greef

Chief Financial OfficerMr. Troy Wichterman CPA

Chief Technology OfficerMr. Sean Werner Ph.D.

Chairman of Scientific Advisory BoardDr. Aby J. Mathew Ph.D.

Chief Commercial OfficerMr. Todd Berard

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Partners Master Fund, L	10% Owner	May 21 '26	Sale	23.70	650,000	15,405,000	4,757,165	May 21 07:10 PM
Casdin Partners Master Fund, L	10% Owner	May 19 '26	Sale	22.65	300,000	6,795,000	5,657,165	May 21 07:10 PM
Casdin Partners Master Fund, L	10% Owner	May 20 '26	Sale	23.70	250,000	5,925,000	5,407,165	May 21 07:10 PM
Casdin Partners Master Fund, L	10% Owner	May 21 '26	Proposed Sale	24.00	650,000	15,600,000		May 21 07:04 PM
Casdin Partners Master Fund, L	10% Owner	May 20 '26	Proposed Sale	24.00	250,000	6,000,000		May 20 07:26 PM
Casdin Partners Master Fund, L	10% Owner	May 19 '26	Proposed Sale	22.30	300,000	6,690,000		May 19 06:25 PM
Foster Karen A.	Chief Quality and Operations	Mar 23 '26	Sale	19.17	2,577	49,401	108,758	Mar 31 05:19 PM
KAREN FOSTER	Officer	Mar 23 '26	Proposed Sale	18.85	2,577	48,576		Mar 23 04:38 PM
Foster Karen A.	Chief Quality and Operations	Mar 05 '26	Sale	20.15	96,923	1,952,998	113,742	Mar 09 06:11 PM
Foster Karen A.	Chief Quality and Operations	Mar 09 '26	Sale	20.00	500	10,000	113,242	Mar 09 06:11 PM
KAREN FOSTER	Officer	Mar 09 '26	Proposed Sale	19.86	500	9,930		Mar 09 04:38 PM
Werner Sean	Chief Technology Officer	Mar 03 '26	Sale	20.74	111	2,302	49,932	Mar 05 05:10 PM
Foster Karen A.	Chief Quality and Operations	Mar 03 '26	Sale	20.74	418	8,669	210,665	Mar 05 05:10 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Mar 03 '26	Sale	20.74	529	10,971	392,937	Mar 05 05:10 PM
Wichterman Troy	Chief Financial Officer	Mar 03 '26	Sale	20.74	588	12,195	220,649	Mar 05 05:10 PM
Aebersold Sarah	Chief Human Resources Officer	Mar 03 '26	Sale	20.74	219	4,542	93,360	Mar 05 05:10 PM
Berard Todd	Chief Marketing Officer	Mar 03 '26	Sale	20.74	353	7,321	165,940	Mar 05 05:10 PM
KAREN FOSTER	Officer	Mar 05 '26	Proposed Sale	20.67	96,923	2,003,398		Mar 05 04:52 PM
Wichterman Troy	Chief Financial Officer	Jan 06 '26	Sale	25.59	990	25,334	150,746	Jan 08 05:04 PM
Foster Karen A.	Chief Quality and Operations	Jan 06 '26	Sale	25.59	335	8,573	191,984	Jan 08 05:04 PM
Aebersold Sarah	Chief Human Resources Officer	Jan 06 '26	Sale	25.59	241	6,167	75,765	Jan 08 05:04 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Jan 06 '26	Sale	25.59	405	10,364	349,350	Jan 08 05:04 PM
Berard Todd	Chief Marketing Officer	Jan 06 '26	Sale	25.59	344	8,803	132,564	Jan 08 05:03 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Dec 09 '25	Sale	25.13	631	15,857	349,755	Dec 17 05:26 PM
Wichterman Troy	Chief Financial Officer	Dec 09 '25	Sale	25.13	1,033	25,959	151,736	Dec 17 05:26 PM
Aebersold Sarah	Chief Human Resources Officer	Dec 15 '25	Sale	24.46	713	17,440	76,006	Dec 17 05:26 PM
Aebersold Sarah	Chief Human Resources Officer	Dec 09 '25	Sale	25.13	233	5,855	76,719	Dec 17 05:26 PM
DuRoss Amy	Director	Dec 15 '25	Sale	24.60	2,000	49,200	18,687	Dec 17 05:25 PM
Berard Todd	Chief Marketing Officer	Dec 09 '25	Sale	25.13	358	8,997	132,908	Dec 17 05:25 PM
Foster Karen A.	Chief Quality and Operations	Dec 09 '25	Sale	25.13	519	13,042	192,319	Dec 17 05:25 PM
SARAH AEBERSOLD	Officer	Dec 15 '25	Proposed Sale	24.39	713	17,390		Dec 15 04:16 PM
Wichterman Troy	Chief Financial Officer	Dec 04 '25	Sale	25.72	30,000	771,600	152,769	Dec 05 06:44 PM
TROY WICHTERMAN	Officer	Dec 04 '25	Proposed Sale	25.72	30,000	771,504		Dec 04 04:42 PM
DuRoss Amy	Director	Nov 26 '25	Sale	27.00	2,000	54,000	20,687	Nov 28 05:39 PM
DuRoss Amy	Director	Nov 25 '25	Sale	27.00	2,000	54,000	22,687	Nov 28 05:39 PM
Berard Todd	Chief Marketing Officer	Nov 25 '25	Sale	26.74	351	9,386	133,266	Nov 28 05:35 PM
Wichterman Troy	Chief Financial Officer	Nov 25 '25	Sale	26.74	584	15,616	182,769	Nov 28 05:35 PM
Aebersold Sarah	Chief Human Resources Officer	Nov 25 '25	Sale	26.74	217	5,803	76,952	Nov 28 05:35 PM
Foster Karen A.	Chief Quality and Operations	Nov 25 '25	Sale	26.74	415	11,097	192,838	Nov 28 05:35 PM
Werner Sean	Chief Technology Officer	Nov 25 '25	Sale	26.74	110	2,941	25,927	Nov 28 05:35 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Nov 25 '25	Sale	26.74	526	14,065	350,386	Nov 28 05:35 PM
DuRoss Amy	Director	Nov 20 '25	Sale	24.51	4,523	110,859	25,687	Nov 21 06:34 PM
DuRoss Amy	Director	Nov 21 '25	Sale	26.00	1,000	26,000	24,687	Nov 21 06:34 PM
DuRoss Amy	Director	Nov 19 '25	Sale	24.50	477	11,686	30,210	Nov 21 06:34 PM
DE GREEF RODERICK	President and CEO	Nov 11 '25	Sale	26.15	35,417	926,155	454,581	Nov 13 05:18 PM
DE GREEF RODERICK	President and CEO	Nov 12 '25	Sale	25.88	33,418	864,858	421,163	Nov 13 05:18 PM
DE GREEF RODERICK	President and CEO	Nov 13 '25	Sale	25.33	31,165	789,409	389,998	Nov 13 05:18 PM
RODERICK DE GREEF	Officer	Nov 13 '25	Proposed Sale	25.33	31,165	789,297		Nov 13 04:30 PM
RODERICK DE GREEF	Officer	Nov 12 '25	Proposed Sale	25.88	33,418	864,995		Nov 12 04:34 PM
DuRoss Amy	Director	Nov 12 '25	Proposed Sale	26.38	12,000	316,560		Nov 12 09:32 AM
RODERICK DE GREEF	Officer	Nov 11 '25	Proposed Sale	26.15	35,417	926,091		Nov 12 08:46 AM
GOSWAMI JOYDEEP	Director	Oct 24 '25	Sale	28.99	1,666	48,297	44,986	Oct 28 05:14 PM
DE GREEF RODERICK	President and CEO	Oct 22 '25	Sale	27.30	37,795	1,031,804	489,998	Oct 24 05:03 PM
DE GREEF RODERICK	Officer	Oct 22 '25	Proposed Sale	27.30	37,795	1,031,807		Oct 22 06:21 PM
Werner Sean	Chief Technology Officer	Oct 20 '25	Sale	27.82	275	7,650	26,037	Oct 22 05:02 PM
Casdin Partners Master Fund, L	10% Owner	Oct 15 '25	Sale	28.55	750,000	21,410,325	5,957,165	Oct 17 07:55 PM
GOSWAMI JOYDEEP	Director	Oct 16 '25	Proposed Sale	30.99	9,000	278,910		Oct 16 02:45 PM
Casdin Partners Master Fund, L	10% Owner	Oct 15 '25	Proposed Sale	28.55	750,000	21,410,325		Oct 15 09:16 PM
Wichterman Troy	Chief Financial Officer	Oct 09 '25	Sale	27.36	833	22,791	183,353	Oct 14 05:30 PM
Berard Todd	Chief Marketing Officer	Oct 09 '25	Sale	27.36	289	7,907	133,617	Oct 14 05:30 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Oct 09 '25	Sale	27.36	509	13,926	350,912	Oct 14 05:30 PM
Aebersold Sarah	Chief Human Resources Officer	Oct 09 '25	Sale	27.36	188	5,144	77,169	Oct 14 05:30 PM
Foster Karen A.	Chief Quality and Operations	Oct 09 '25	Sale	27.36	419	11,464	193,253	Oct 14 05:30 PM
Aebersold Sarah	Chief Human Resources Officer	Sep 15 '25	Sale	25.61	714	18,286	77,357	Sep 17 05:43 PM
Foster Karen A.	Chief Quality and Operations	Sep 11 '25	Sale	26.83	511	13,710	193,672	Sep 15 05:02 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Sep 11 '25	Sale	26.83	630	16,903	351,421	Sep 15 05:02 PM
Wichterman Troy	Chief Financial Officer	Sep 11 '25	Sale	26.83	1,032	27,689	184,186	Sep 15 05:02 PM
Berard Todd	Chief Marketing Officer	Sep 11 '25	Sale	26.83	358	9,605	133,906	Sep 15 05:02 PM
Aebersold Sarah	Chief Human Resources Officer	Sep 11 '25	Sale	26.83	233	6,251	78,071	Sep 15 05:02 PM
Werner Sean	Chief Technology Officer	Sep 11 '25	Sale	26.83	72	1,932	26,312	Sep 15 05:01 PM
SARAH AEBERSOLD	Officer	Sep 15 '25	Proposed Sale	25.51	714	18,214		Sep 15 04:30 PM
Mathew Aby J.	EVP & Chief Scientific Officer	Aug 26 '25	Sale	25.44	531	13,509	352,051	Aug 28 05:07 PM
Foster Karen A.	Chief Quality and Operations	Aug 26 '25	Sale	25.44	413	10,507	194,183	Aug 28 05:07 PM
Werner Sean	Chief Technology Officer	Aug 26 '25	Sale	25.44	111	2,824	26,384	Aug 28 05:07 PM
Wichterman Troy	Chief Financial Officer	Aug 26 '25	Sale	25.44	590	15,010	185,218	Aug 28 05:07 PM
Aebersold Sarah	Chief Human Resources Officer	Aug 26 '25	Sale	25.44	219	5,571	78,304	Aug 28 05:07 PM
Berard Todd	Chief Marketing Officer	Aug 26 '25	Sale	25.44	354	9,006	134,264	Aug 28 05:06 PM
Berard Todd	Chief Marketing Officer	Aug 25 '25	Sale	25.53	10,000	255,300	124,618	Aug 27 05:00 PM
TODD C.J. BERARD	Officer	Aug 25 '25	Proposed Sale	25.53	10,000	255,265		Aug 25 04:37 PM

Open in Screener

MXCT

MaxCyte Inc

1.32

Aug 17 • 7:01 AM ET -0.00 (-0.01%)

Healthcare Medical Devices USA Micro NASD

Peers: INGN LUCD NNOX OWLT MASS RXST SENS SGHT TLSI ELMD

| Held by: VTI VXF VHT BTEC

Index	-
Market Cap	136.22M
Enterprise Value	47.78M
Income	-35.64M
Sales	31.05M
Book/sh	1.50
Cash/sh	1.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	91
IPO	Dec 05, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	4.39
P/B	0.88
P/C	1.29
P/FCF	-
EV/EBITDA	-
EV/Sales	1.54
Quick Ratio	11.47
Current Ratio	12.26
Debt/Eq	0.11
LT Debt/Eq	0.10
Option/Short	Yes / Yes

EPS (ttm)	-0.33
EPS next Y	-0.26
EPS next Q	-0.08
EPS this Y	33.73%
EPS next Y	6.59%
EPS next 5Y	21.91%
EPS past 3/5Y	-21.85% -19.78%
Sales past 3/5Y	-9.30% 4.76%
EPS Y/Y TTM	21.12%
Sales Y/Y TTM	-13.15%
EPS Q/Q	28.42%
Sales Q/Q	-14.53%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	11.11% 11.75%

Insider Own	7.77%
Insider Trans	-0.13%
Inst Own	58.66%
Inst Trans	-16.13%
ROA	-17.62%
ROE	-20.39%
ROIC	-20.42%
Gross Margin	66.17%
Oper. Margin	-103.98%
Profit Margin	-114.77%
SMA20	14.58%
SMA50	10.12%
SMA200	15.79%
Trades

Shs Outstand	106.13M
Shs Float	98.80M
Short Float	1.26%
Short Ratio	1.03
Short Interest	1.24M
52W High	1.87 -29.23%
52W Low	0.64 105.14%
Volatility	13.12% 8.30%
ATR (14)	0.10
RSI (14)	60.80
Beta	1.55
Rel Volume	0.10
Avg Volume	1.21M
Volume	6,002

Perf Week	9.08%
Perf Month	6.44%
Perf Quarter	26.91%
Perf Half Y	83.42%
Perf YTD	-14.85%
Perf Year	-2.95%
Perf 3Y	-63.84%
Perf 5Y	-91.17%
Perf 10Y	-
Recom	1.33
Target Price	4.10
Prev Close	1.32
Price	1.32
Change %	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	BTIG Research	Buy → Neutral
Aug-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Aug-13-26 01:03AM	MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... (GuruFocus.com) +9.45%
Aug-12-26 09:50PM	MaxCyte, Inc. Q2 2026 Earnings Call Summary (Moby)
04:05PM	MaxCyte Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-21-26 08:05AM	MaxCyte Announces Multi-Platform Technology License Partnership with Genentech to Advance Cell Therapy Development (GlobeNewswire) +5.13%
Jul-15-26 04:05PM	MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
01:01AM	Loading…
May-13-26 01:01AM	MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... (GuruFocus.com) +24.06%
May-12-26 08:53PM	MaxCyte, Inc. Q1 2026 Earnings Call Summary (Moby)
04:05PM	MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance (GlobeNewswire)
Apr-29-26 04:05PM	MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 (GlobeNewswire) -6.78% +7.63%
Mar-31-26 04:05PM	MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.92%
Mar-25-26 08:30AM	MaxCyte, Inc. Q4 2025 Earnings Call Summary (Moby) -6.81%
Mar-24-26 11:01PM	MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance (GlobeNewswire)
Mar-23-26 08:05AM	MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer (GlobeNewswire)
Feb-25-26 05:46AM	MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery (Insider Monkey)
08:05AM	Loading…
Feb-24-26 08:05AM	MaxCyte unveils ExPERT DTx, a 96-well electroporation platform to accelerate discovery (GlobeNewswire) +5.01%
Feb-23-26 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 (GlobeNewswire)
Jan-12-26 08:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-01-25 09:00AM	Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO (Business Wire) -7.39%
Nov-13-25 12:01AM	MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges (GuruFocus.com)
Nov-12-25 04:08PM	MaxCyte Announces Planned CFO Transition in 2026 (GlobeNewswire)
04:05PM	MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +5.44%
Nov-07-25 08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-05-25 08:05AM	MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
Oct-08-25 08:05AM	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.68%
Oct-06-25 08:05AM	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors (GlobeNewswire)
Sep-22-25 04:30PM	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability (GlobeNewswire) +10.32%
Aug-11-25 07:45AM	MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio (Insider Monkey)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -29.90%
04:05PM	Loading…
04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 10:27AM	MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-31-25 08:05AM	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire)
Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

PresidentMr. Maher Masoud

Chief Financial OfficerMr. Parmeet Ahuja

Chief Operations OfficerMr. Jay Gelfman

Senior Vice President of Corporate DevelopmentMr. Jack Horgan

Senior Vice President of Global SalesMs. Ana-Paula Martins Fernandes

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 17 '26	Sale	0.81	10,142	8,266	151,669	Mar 19 04:05 PM

LAB

Standard BioTools Inc

BLFS

Biolife Solutions Inc

MXCT

MaxCyte Inc

Upgrade your Finviz experience